Current potential and challenges in the advances of liquid crystalline nanoparticles as drug delivery systems

Madheswaran T 1 , Kandasamy M 2 , Bose RJ 3 , Karuppagounder V 4

Affiliations 

  • 1 Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, No. 126 Jalan Jalil Perkasa 19, Bukit Jalil, Kuala Lumpur, 57000, Malaysia. Electronic address: thiagupharma@gmail.com
  • 2 Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, No. 126 Jalan Jalil Perkasa 19, Bukit Jalil, Kuala Lumpur, 57000, Malaysia
  • 3 Molecular Imaging Program at Stanford (MIPS) and the Canary Center at Stanford for Cancer Early Detection, Department of Radiology, School of Medicine, Stanford University, Stanford, CA 94305-5427, USA
  • 4 Department of Orthopedics and Rehabilitation, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033, USA. Electronic address: vengadeshprabu@gmail.com
Drug Discov Today, 2019 07;24(7):1405-1412.
PMID: 31102731 DOI: 10.1016/j.drudis.2019.05.004

Abstract

Lyotropic nonlamellar liquid crystalline nanoparticles (NPs) (LCN), such as cubosomes and hexosomes, are useful tools for applications in drug delivery because of their unique structural properties. LCNs are highly versatile carriers that can be applied for use with topical, oral, and intravenous treatments. In recent years, significant research has focused on improving their preparation and characterization, including controlling drug release and enhancing the efficacy of loaded bioactive molecules. Nevertheless, the clinical translation of LCN-based carriers has been slow. In this review, we highlight recent advances and challenges in the development and application of LCN, providing examples of their topical, oral, and intravenous drug delivery applications, and discussing translational obstacles to LCN as a NP technology.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications